10-Q: Sharps Tech Secures Capital, Posts First Revenue Amid Losses

Sentiment:

Quarterly Report 13 August 2025 5:22 PM

Sharps Technology, Inc. reported its first revenue in Q2 2025, bolstered by a significant capital raise, but continues to face operational losses and going concern doubts.

Delay expectedThe Asset Purchase Agreement with Nephron and Nephrons InjectEZ, LLC, which involved a $1 million escrow deposit, was not consummated, and the deposit was forfeited. The company is not actively working towards further amendment, and closing is contingent on future amendments and necessary financing.Commercialization of the Sharps Provensa product line is affected by insufficient capital for required research & development, and a timeline for future R&D and commercialization cannot be determined.The Supply Agreement with Stericare Solutions, LLC, initially targeted to commence in November 2024, had its initial purchase order received on April 30, 2025, and shipments commenced in Q2 2025, indicating a delay from the original target.

Capital raiseThe company closed an offering on January 29, 2025, receiving gross proceeds of approximately $20.0 million ($18.2 million net proceeds), which included Common Units and Pre-Funded Units, along with Series A and Series B Registered Common Warrants.The company intends to finance its future development, commercialization activities, and working capital needs largely from the sale of equity securities and/or additional funding from other traditional financing sources.A portion of the January 2025 offering proceeds will be allocated to expanding production capacity in Hungary.The company entered into subscription agreements on December 5, 2024, issuing 828 shares of Common Stock for gross proceeds of $484,438.The company entered into subscription agreements on May 31 and June 13, 2024, issuing 636 shares of Common Stock for gross proceeds of $1.6 million.Warrant inducements offered on May 30, 2024, resulted in 869 warrants being exercised, generating gross proceeds of $1.9 million.The company completed two simultaneous offerings on September 29, 2023, yielding aggregate gross proceeds of approximately $5.6 million.A securities purchase agreement completed on February 3, 2023, resulted in net proceeds of approximately $3.2 million.The company's Initial Public Offering (IPO) in April 2022 generated net proceeds of approximately $14.2 million.

Worse than expectedOperating loss increased to $(5,028,151) for the six months ended June 30, 2025, compared to $(3,765,152) in the prior year period, indicating a deterioration in core operational performance.Cash used in operating activities increased to $(4,355,930) for the six months ended June 30, 2025, from $(3,528,676) in the prior year, signaling an accelerated cash burn from core business activities.A negative gross margin of $(1,032,027) was reported, primarily due to a significant inventory reserve and excess manufacturing costs, which is a concerning indicator of product profitability.The reported net income of $5,488,141 was predominantly driven by a non-cash fair market value adjustment gain on warrants of $11,087,700, masking the underlying operational losses.The company continues to disclose substantial doubt about its ability to continue as a going concern, highlighting persistent financial instability despite recent capital raises.

Summary

Sharps Technology, Inc. generated its first product revenue of $222,722 for the six months ended June 30, 2025, primarily from Securegard and Sologard syringes.
The company reported a net income of $5,488,141 for the six months ended June 30, 2025, largely driven by an $11,087,700 non-cash fair market value adjustment gain on warrants.
Operating loss increased to $(5,028,151) for the six months ended June 30, 2025, compared to $(3,765,152) in the prior year period.
A negative gross margin of $(1,032,027) was recorded for the six months ended June 30, 2025, including a $730,086 inventory reserve due to market factors like global tariffs and $199,000 in excess manufacturing costs.
Cash balance significantly increased to $8,322,192 at June 30, 2025, from $864,041 at December 31, 2024, following net proceeds of $18.2 million from a January 2025 offering.
Working capital improved to $8,081,406 at June 30, 2025, from a deficiency of $(2,011,679) at December 31, 2024.
The company repaid an outstanding note of $4,222,012 in January 2025, becoming debt-free.
Nasdaq listing compliance was regained on May 21, 2025, after previous non-compliance notices regarding minimum bid price and stockholders' equity.
The Sharps Provensa product line's commercialization is hindered by insufficient capital for research and development, with no determined timeline for future R&D.
The company is involved in multiple legal proceedings with a former co-founder and a supplier, totaling claims of over $2.2 million against the company.

Sentiment

Score: 4

Explanation: While the company has significantly improved its liquidity through a substantial capital raise and has commenced generating its first revenue, the underlying operational performance shows increased losses and cash burn, a negative gross margin, and continued going concern doubt. The reported net income is primarily due to a non-cash warrant revaluation gain. Delays in product commercialization and ongoing litigation also weigh on sentiment. The capital raise is positive for immediate liquidity but highlights ongoing reliance on external funding for sustained operations.

Positives

Commenced generating product revenue of $222,722 in the second quarter of 2025, marking a significant milestone.
Achieved a substantial increase in cash balance to $8,322,192 at June 30, 2025, from $864,041 at December 31, 2024, due to successful financing.
Improved working capital to $8,081,406 at June 30, 2025, from a deficiency of $(2,011,679) at December 31, 2024.
Became debt-free by repaying a $4,222,012 note with proceeds from the January 2025 offering.
Regained compliance with Nasdaq listing requirements for minimum bid price and stockholders' equity.
Secured a supply agreement with Stericare Solutions, LLC for 520 million units of Sologard syringes, with expected revenues exceeding $50 million, and received an initial purchase order for $400,000.

Negatives

Reported a negative gross margin of $(1,032,027) for the six months ended June 30, 2025, due to a $730,086 inventory reserve and excess manufacturing costs.
Operating loss increased to $(5,028,151) for the six months ended June 30, 2025, compared to $(3,765,152) in the prior year period.
Cash used in operating activities increased to $(4,355,930) for the six months ended June 30, 2025, indicating continued cash burn.
Substantial doubt remains regarding the company's ability to continue as a going concern without raising additional financing.
Insufficient capital continues to hinder required research and development for the Sharps Provensa product line, affecting its future commercialization.
Forfeited a $1,000,000 escrow deposit related to an unconsummated Asset Purchase Agreement with Nephron/InjectEZ.
Selling, General and Administrative expenses increased by $465,237 for the six months ended June 30, 2025, primarily due to higher professional services and manufacturing plant operating costs.

Risks

The company's ability to continue as a going concern is dependent on raising sufficient financing and commercializing its products into a profitable business.
Insufficient capital for research and development of the Sharps Provensa product line may prevent its future commercialization.
Operations and financial results could be adversely affected by international trade policies, including recent tariffs.
Ongoing legal proceedings with former co-founder Barry Berler, including claims for $456,000 in damages and $500,000 under a royalty agreement, pose financial and operational risks.
A lawsuit from Plastomold Industries Ltd. claiming $1.762 million for alleged unpaid invoices and defective machinery presents significant litigation risk.
Fair Market Value (FMV) adjustments on outstanding warrants, which are classified as liabilities, can cause significant fluctuations in reported operating results.
Future development, commercialization activities, and working capital needs are largely dependent on the sale of equity securities and/or additional funding from other traditional financing sources.

Future Outlook

The company intends to finance its future development, commercialization activities, and working capital needs primarily through the sale of equity securities and/or additional funding from traditional financing sources until operations generate sufficient funds. It is committed to driving revenue growth from Securegard and Sologard projects in 2025 and plans to secure manufacturing capacity for next-generation polymer-based prefillable syringes. A portion of the January 2025 offering proceeds will be used to expand production capacity in Hungary. The company is not actively pursuing further amendments to the Asset Purchase Agreement with Nephron/InjectEZ, and its closing remains contingent on future amendments and necessary financing. The company is also evaluating the impacts of new accounting standards and the recently enacted One Big Beautiful Bill Act (OBBBA) on its financial statements.

Management Comments

"We have reported net income of $5,488,141, see MD&A relating to reported FMV gain of $11,087,700 on warrants, and incurred a net loss of $3,084,713 for the period six months ended June 30, 2025 and 2024, respectively."
"The accompanying financial statements have been prepared assuming that the Company will continue as a going concern."
"The Company has not generated any cash flow from operations since inception, but commenced generating revenues in the second quarter of 2025."
"As of June 30, 2025, the Company had working capital of $8,081,406 which is not expected to be sufficient to fund the Companys planned operations for the next 12 months. These factors raise substantial doubt regarding the Companys ability to continue as a going concern."
"The Companys ability to continue as a going concern is dependent upon the Companys ability to commercialize its products into a profitable business or raise sufficient financing."
"The Company intends to finance its commercialization activities and its working capital needs largely from the sale of equity securities and/or with additional funding from other traditional financing sources until such time that funds provided by operations are sufficient to fund working capital requirements."
"As of the close of the January 2025 Offering and concurrent repayment of an outstanding Note, the Company is debt free."
"As previously disclosed, there continues to be insufficient capital to fund required research & development for the Sharps Provensa product line, which will affect any future commercialization."
"At this time the Company is not able to determine a timeline for future research and development and commercialization of the Provensa product."
"With the recent financing secured, the Company believes that it is positioned to advance its growth strategy by utilizing its working capital to support essential operating expenses."
"Production is currently on track, with the Company commencing revenue in the quarter ended June 30, 2025."

Industry Context

The company operates within the medical device and pharmaceutical packaging industry, specifically focusing on safety syringes. Its strategic emphasis on manufacturing and distribution of its patented products, including Securegard and Sologard, aligns with the industry's demand for advanced and safe medical delivery systems. The pursuit of large supply agreements, such as the one with Stericare Solutions, reflects a competitive strategy to establish market presence and scale production. The mention of global tariffs indicates the company's exposure to broader international trade policy trends affecting manufacturing costs and supply chain stability in the medical sector. The ongoing investment in 'advanced production technology' and 'next generation polymer-based prefillable syringes' suggests a commitment to innovation and efficiency, which are critical drivers in the evolving healthcare market.

Comparison to Industry Standards

The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks. Therefore, a direct comparison to industry standards with specific entities or metrics is not possible based on the provided information.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	Robert M. Hayes	NA	2025-08-11	Notified of Non-Renewal of Employment Agreement.
Executive Chairperson	NA	Paul K. Danner	2025-07-01	Appointment to new role; previously served as a Director and Audit Committee Chairperson.
Co-Chairman and Board Member	Alan Blackman	NA	2024-08-31	Separation agreement and full payment of severance; Series A Preferred Stock cancelled and forfeited.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Authorized Common Stock Increase	Shareholders approved an increase of authorized common stock from 100,000,000 to 500,000,000 shares.	2024-07-31	Increases flexibility for future equity raises and stock-based compensation, but also potential for dilution.
Reverse Stock Split Authorization	Shareholders approved a proposal to authorize the Board to effect a reverse stock split at a ratio not exceeding 1-for-22.	2024-10-07	Aimed at increasing share price to meet Nasdaq listing requirements, but can reduce liquidity and may not prevent further price declines.
Reverse Stock Split Implementation	A 1-for-22 reverse stock split was implemented.	2024-10-15	Reduced the number of outstanding shares and increased the per-share price to help maintain Nasdaq listing.
Authorized Share Reduction & Reverse Stock Split	Board approved an amendment to reduce authorized shares from 500,000,000 to 1,666,667 and effectuated a 1-for-300 reverse stock split of outstanding common shares.	2025-04-27	Further reduced outstanding shares and increased per-share price, addressing Nasdaq compliance and potentially signaling a more controlled capital structure, but also indicating significant prior dilution.
Equity Incentive Plan Approval	Shareholders approved the 2024 Equity Incentive Plan, providing for the issuance of up to 883 options and/or restricted stock.	2024-12-19	Provides incentives for officers, directors, employees, and consultants, aligning their interests with shareholders but potentially leading to future dilution.
Nasdaq Listing Compliance	Nasdaq notified the company that it met the required listing requirements after previous non-compliance notices.	2025-05-21	Positive for investor confidence and continued trading on a major exchange, reducing delisting risk.

Legal Proceedings

**Barry Berler Lawsuit (Case No. 2:24-cv-04787, filed July 10, 2024)**: Claims for $456,000 in damages for alleged breach of consulting agreement ($52,500), failure to pay a bonus ($216,000), and 50% of Mr. Blackman's severance payment ($187,500). Also seeks a declaration of ownership of 50% of the company's Series A Preferred Stock (which is no longer outstanding) and an injunction. The company has accrued for unpaid consulting fees but believes other claims are without merit and is vigorously defending, having filed an answer and counterclaims, including third-party claims against Plastomold Industries Ltd., Plasto Design Ltd, and Plasto Design Solutions. This case is in the discovery stage.
**Barry Berler Arbitration (filed June 17, 2024)**: Demand for arbitration under AAA rules asserting claims for payment of $500,000 plus interest under the company's royalty agreement, rescission thereof, and reversion of intellectual property rights. The company believes these claims are without merit and is vigorously defending, having filed an answer with counterclaims. This proceeding is in the discovery stage.
**Plastomold Industries Ltd. Lawsuit (Case No. 2:24-CV-02580, filed April 3, 2024)**: Claims for $1.762 million in damages for alleged failure to pay invoices (approximately $1 million related to a maintenance agreement for defective machinery), breach of implied covenant of good faith and fair dealing, unjust enrichment, and conversion. The company believes these claims are without merit and is vigorously defending, having filed an answer, affirmative defenses, and a counterclaim for damages that the company believes would exceed Plastomold's claims, based on the insufficiency of Plastomold's services and defective machinery. This proceeding is in the discovery stage.

Related Party Transactions

Accounts payable and accrued liabilities include $22,000 (June 30, 2025) and $99,500 (December 31, 2024) payable to officers and directors, which are unsecured, non-interest bearing, and due on demand.
A royalty agreement with Barry Berler (co-founder) entitles him to a 2% royalty of net sales derived from certain intellectual property, with a potential single payment of $500,000 to cancel future obligations, which has not yet been made.
Paul Danner, the company's Executive Chairperson, purchased five shares of the company's Series B Preferred Stock for $20.00 per share subsequent to June 30, 2025.
Alan Blackman, a former co-chairman and director, received severance payments of approximately $346,000 plus medical benefits, which were fully paid by August 31, 2024, in connection with his separation agreement.

Stakeholder Impact

**Shareholders**: Experienced significant dilution from recent equity offerings and warrant exercises. The multiple reverse stock splits (1-for-22 and 1-for-300) have drastically reduced the number of outstanding shares, impacting per-share metrics. Regaining Nasdaq compliance is positive for listing status, but continued going concern doubt and potential for future dilution from ongoing financing needs remain key risks.
**Employees**: A shift in company activities from research and development to manufacturing is noted. Changes in key management roles, including the non-renewal of the CEO's employment agreement and the appointment of a new Executive Chairperson, may impact organizational stability and direction.
**Customers**: The commencement of revenue generation and the securing of a large supply agreement with Stericare Solutions, LLC, indicate improved product availability and potential for increased sales and market penetration for Securegard and Sologard products.
**Creditors**: The company's repayment of its outstanding note and current debt-free status is a positive development for creditors, reducing immediate financial leverage risk.
**Suppliers**: Ongoing capital expenditures for machinery and molds suggest continued investment and potential for new or expanded supplier relationships. However, the ongoing litigation with Plastomold Industries Ltd. (a supplier) highlights potential risks in supplier relationships and contract disputes.

Next Steps

Continue commercialization efforts for Securegard and Sologard products.
Expand production capacity in Hungary, including the purchase, installation, and operational qualification of advanced machinery and facility upgrades.
Fulfill shipments under the Stericare Solutions, LLC purchase order and pursue ongoing activities with other European companies.
Secure manufacturing capacity for the company's next-generation polymer-based prefillable syringes.
Monitor and potentially re-engage in discussions for further amendments and necessary financing for the Asset Purchase Agreement with Nephron/InjectEZ.
Continue to vigorously defend against ongoing legal proceedings initiated by Barry Berler and Plastomold Industries Ltd.
Evaluate the impacts of newly issued accounting pronouncements (ASU 2023-09, ASU 2024-03) and the One Big Beautiful Bill Act (OBBBA) on future financial disclosures.

Key Dates

Date	Description
2017-12-11	Company incorporated in Wyoming.
2018-02-01	Series A Preferred Stock issued to Alan Blackman.
2019-04-18	Authorized common stock increased to 50,000,000 shares.
2022-04-13	Company's Initial Public Offering (IPO) deemed effective by the SEC.
2022-04-14	Company's common stock and warrants began trading on the Nasdaq Capital Market.
2022-04-19	Company received net proceeds of $14.2 million from the IPO.
2022-07-06	Acquisition of Safegard Medical (Hungary) KFT closed.
2022-09-30	Formal employment agreement entered into with Andrew R. Crescenzo as Chief Financial Officer.
2023-01-24	Company's Board of Directors adopted the 2023 Equity Incentive Plan.
2023-02-03	Company completed a securities purchase agreement with institutional investors, receiving net proceeds of approximately $3.2 million.
2023-09-29	Company completed two simultaneous offerings (Shelf Offering and Private Placement), receiving aggregate gross proceeds of approximately $5.6 million.
2023-11-10	Company executed an Employment Agreement with Robert Hayes, its Chief Executive Officer, amending a prior employment letter.
2024-04-03	Plastomold Industries Ltd. commenced a lawsuit against the Company.
2024-05-20	Company entered into an Amendment to the Asset Purchase Agreement with Nephron and Nephrons InjectEZ, LLC.
2024-05-30	Company offered warrant inducements to certain warrant holders.
2024-05-31	Company entered into subscription agreements with institutional investors, issuing shares for gross proceeds of $1.6 million.
2024-06-13	Company entered into additional subscription agreements with institutional investors, part of the $1.6 million gross proceeds.
2024-06-17	Barry Berler filed a demand for arbitration against the Company.
2024-07-10	Barry Berler commenced a lawsuit against Sharps Technology, Inc. and Alan Blackman.
2024-07-19	Escrow deposit of $1,000,000 related to the Asset Purchase Agreement with Nephron was released to the Seller and recorded as a forfeited agreement cost.
2024-07-24	Company entered into a Supply Agreement with Stericare Solutions, LLC.
2024-08-31	Severance payments to Alan Blackman were fully paid, and his Series A Preferred Stock was cancelled and forfeited.
2024-09-20	Company entered into a securities purchase agreement and a Senior Secured Note for an aggregate principal amount of $4,375,000.
2024-10-07	Shareholders approved a proposal to authorize the Board to effect a reverse stock split.
2024-10-15	A 1-for-22 reverse stock split was effective.
2024-12-05	Company entered into subscription agreements with institutional investors, issuing shares for gross proceeds of $484,438.
2024-12-19	Company's Shareholders approved and the Board of Directors adopted the 2024 Equity Incentive Plan.
2025-01-29	Company closed on an offering (the 2025 Offering), receiving gross proceeds of approximately $20.0 million.
2025-03-12	Nasdaq notified the company of non-compliance with the minimum bid price requirement.
2025-03-28	Stockholders approved a reset of the exercise price for the 2025 Warrants.
2025-04-03	Nasdaq notified the company of non-compliance with the $2,500,000 stockholders equity requirement.
2025-04-23	Board approved an Amendment to the Certificate of Incorporation to reduce authorized shares and effectuate a 1-for-300 reverse stock split.
2025-04-27	The 1-for-300 reverse stock split was effective.
2025-04-30	Company received the initial purchase order under the Supply Agreement with Stericare Solutions, LLC for $400,000.
2025-05-21	Nasdaq notified the company that it met the required listing requirements.
2025-06-30	End of the current quarterly reporting period.
2025-07-01	Paul Danner's appointment as Executive Chairperson became effective.
2025-07-04	The One Big Beautiful Bill Act (OBBBA) was enacted in the U.S.
2025-08-11	Company notified Robert Hayes of Non-Renewal of his Employment Agreement.
2025-08-13	Company executed an Employment Agreement with Paul Danner.

Recommendation

hold

While Sharps Technology, Inc. has significantly improved its liquidity and working capital through a substantial capital raise and has achieved its first product revenue, the underlying operational performance remains weak. The company reported increased operating losses and a negative gross margin, with the reported net income primarily attributable to a non-cash accounting gain on warrants. The persistent 'going concern' doubt, ongoing legal challenges, and delays in key product commercialization indicate significant risks. The large supply agreement is a positive long-term indicator, but the company's ability to execute profitably and resolve its fundamental operational challenges is yet to be proven. Given this mixed financial picture, a 'hold' recommendation is appropriate, advising investors to monitor the company's progress on achieving sustainable profitability and resolving its financial and legal uncertainties before making further investment decisions.

Keywords

Medical device, Safety syringes, Pharmaceutical packaging, Sharps Technology, STSS, Sologard, Securegard, SEC filing, 10-Q, Financial results, Capital raise, Going concern, Litigation, Nasdaq compliance, Medical technology, Healthcare

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.